Holen Sie sich die Stockscreener-App
230.65
4.85%
10.67
Handel nachbörslich:
230.65
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Resmed Inc Aktie (RMD) Neueste Nachrichten
Resmed Inc Stock (RMD) Moved Up by 3.43% on Aug 19: What Investors Need To Know - TradingKey
Oxbow Advisors LLC Invests $5.57 Million in ResMed Inc. $RMD - MarketBeat
Rothschild Redburn initiates ResMed stock coverage with neutral rating - Investing.com
Rothschild Redburn initiates ResMed stock coverage with neutral rating By Investing.com - Investing.com Canada
Deutsche Bank AG Takes Position in ResMed Inc. $RMD - MarketBeat
Resmed Announces Board Leadership Transition and Director Retirement - The Globe and Mail
ResMed stock slips as Q4 revenue rose 9% - AD HOC NEWS
Resmed board set to get new lead director - HME News
RESMED INC CDI COM USD0.004 (10CDI/1SHS) To Go Ex-Dividend On August 19th, 2026 With 0.066 USD Dividend Per Share - moomoo.com
UNIVEST FINANCIAL Corp Acquires Shares of 12,846 ResMed Inc. $RMD - MarketBeat
Perigon Wealth Management LLC Invests $4.60 Million in ResMed Inc. $RMD - MarketBeat
5,358 Shares in ResMed Inc. $RMD Purchased by Flputnam Investment Management Co. - MarketBeat
Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor - Koreabizwire
ResMed (ASX:RMD) Faces Market Attention as Healthcare Technology Portfolio Continues to Evolve - Kalkine
ResMed (RMD) Announces Auditor Transition to PwC and Board Leade - GuruFocus
ResMed Replaces KPMG with PwC and Names Carol Burt as Lead Director - Kalkine
ResMed names Carol Burt as lead director, Ron Taylor to retire - Investing.com
ResMed Inc. stock falls Monday, underperforms market - MarketWatch
Resmed Names Carol Burt Lead Director as Ron Taylor Retires After 21 Years on Board - quiverquant.com
A lead director's 21-year Resmed tenure is set to end in November - Stock Titan
ResMed’s (RMD) Sleep Business Booms Even As One Product Stumbles - Yahoo Finance
ResMed Inc. (RMD) Stock Analysis: Assessing a 10% Potential Upside in Healthcare Innovation - DirectorsTalk Interviews
Could Cochlear (ASX:COH) and ResMed (ASX:RMD) Shape the Next Chapter? - Kalkine Media
87,722 Shares in ResMed Inc. $RMD Purchased by Avalon Trust Co - MarketBeat
41,381 Shares in ResMed Inc. $RMD Acquired by ABN AMRO Bank N.V. - MarketBeat
Why You Should Consider Buying ResMed Stock After Its First-Ever Annual Guide - TIKR.com
The 5 Most Interesting Analyst Questions From ResMed’s Q2 Earnings Call - Yahoo Finance
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
ResMed Inc.: Financial Data Forecasts Estimates and Expectations | RMEA | AU000000RMD6 - marketscreener.com
ResMed, Inc.: Financial Data Forecasts Estimates and Expectations | RME | US7611521078 - marketscreener.com
ResMed (ASX:RMD) Keeps Dividend Momentum Going: Keep It on Your Radar - Kalkine
ResMed to sell MatrixCare business for $490 million - Minichart
ResMed Inc. Submits Annual 10-K Report for Fiscal Year Ending June 30, 2026 - Kalkine Media
ResMed Inc. Files Annual Form 10-K Report for Fiscal Year Ended June 30, 2026 - Kalkine
ResMed Submits 2026 Fiscal Year-End 10-K Annual Report Detailing Financial and Operational Metrics - Kalkine Media
RESMED INC. : RBC RAISES TARGET PRICE TO $244 FROM $234 - webull.com
RESMED INC FY 2026: Revenue $5.65B, EPS $10.43— 10-K Summary - TradingView
How Investors May Respond To ResMed (RMD) Dividend Hike And Ventilator Recall Headwinds - simplywall.st
Handelsbanken Fonder AB Raises Stock Position in ResMed Inc. $RMD - MarketBeat
Weekly Earnings Wrap: CBA, REA Group, Westpac, Resmed and more - Morningstar Australia
ResMed Inc. Stock 12‑Month Price Target Cut to $258.47, Implies 14% Upside - TradingView
ResMed Could Expand Into More Sleep Disorder Treatments -- Interview - moomoo.com
ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
J.P. Morgan Sticks to Their Buy Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
ResMed (RMD) Stock May Be 31% Undervalued After Soft FY27 Outlook - Yahoo Finance
ASX healthcare share remains cheap despite mixed earnings result - Morningstar Australia
Is Recall-Hit Outlook and Bigger Payout Altering The Investment Case For ResMed (RMD)? - Yahoo Finance
ResMed Chairman and CEO Michael Farrell Sells 4,991 Shares Under 10b5-1 Plan - Kalkine
ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
ResMed CEO Michael Farrell sells $1.03m in company stock By Investing.com - Investing.com India
Insider Selling: ResMed (NYSE:RMD) CEO Sells $1,026,598.79 in Stock - MarketBeat
ResMed CEO Michael Farrell sells $1.03m in company stock - Investing.com
Resmed Insider Sold Shares Worth $1,026,596, According to a Recent SEC Filing - marketscreener.com
Assenagon Asset Management S.A. Grows Stock Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Bull Thinks Five-Year Outlook Is Intact -- Market Talk - moomoo.com
Ord Minnett Remains a Buy on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
Macquarie Keeps Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
Citi Sticks to Their Hold Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
Is It Too Late to Buy ResMed Inc (RMD) After 3.8% Rally? GF Value Says Undervalued - GuruFocus
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
ResMed’s Margin Squeeze and Astral Recall Overshadow Product Rollout and $1.5 Billion Buyback Plan - finance.biggo.com
Operating margin % of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – HAM:RMEA - TradingView
ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh - TradingView
Resmed Inc Stock (RMD) Moved Up by 3.01% on Aug 10: Key Drivers Unveiled - TradingKey
Resmed’s stock falls by 7% on soft FY27 outlook - Medical Device Network
ResMed Inc. (RMD) Stock Analysis: Unveiling a 16.64% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
0.97%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):